Showing 1 – 20 of 614
Relevance | Newest | Oldest |
  • JAMA December 13, 2016

    Figure 1: Flow of Patients Through the GLAGOV Randomized Clinical Trial

    aPatients could be excluded for more than 1 reason; therefore, the sum of the criteria may be greater than the number of patients. CETP indicates cholesterylester transfer protein; GLAGOV, Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound; IVUS, intravascular ultrasonography; LDL-C, low-density lipoprotein cholesterol.bLDL-C level 80 mg/dL (2.07 mmol/L) or greater, with or without risk factors; less than 60 mg/dL (1.55 mmol/L); or 60 mg/dL or greater to less than 80 mg/dL.cClinically significant heart disease (154), hyperthyroidism or hypothyroidism (38), type 1 diabetes (27), history of malignancy (16), fasting triglyceride level greater than 400 mg/dL (4.52 mmol/L) (15), active liver disease or hepatic dysfunction (11), uncontrolled cardiac arrhythmia (4), creatine kinase level greater than 3 times upper limit of normal (2), history of hereditary muscular disorders (2), known active infection or systemic dysfunctions (2), New York Heart Association III or IV heart failure or left ventricular ejection fraction less than 30% (2), severe renal dysfunction (1), uncontrolled hypertension (1).
  • Management of Graves Disease: A Review

    Abstract Full Text
    is active quiz
    JAMA. 2015; 314(23):2544-2554. doi: 10.1001/jama.2015.16535

    This review summarizes use of antithyroid drugs, radioactive iodine, or thyroidectomy in treating Graves disease.

  • Hyperthyroidism

    Abstract Full Text
    JAMA. 2011; 306(3):330-330. doi: 10.1001/jama.306.3.330
  • Thyroid Function and Mortality in Patients Treated for Hyperthyroidism

    Abstract Full Text
    free access
    JAMA. 2005; 294(1):71-80. doi: 10.1001/jama.294.1.71
  • Hyperthyroidism

    Abstract Full Text
    JAMA. 2005; 294(1):146-146. doi: 10.1001/jama.294.1.146
  • JAMA December 1, 2004

    Figure 1: Initial Laboratory Evaluation of a Patient With a Thyroid Nodule >1 cm Detected by Palpation or Ultrasound

    *Cutpoints for low, normal, and high TSH levels vary according to laboratory.†Evaluate for hypothyroidism.‡Evaluate for hyperthyroidism.§Indications for fine-needle aspiration guided by ultrasound include palpable nodule greater than 50% cystic, difficult to palpate or nonpalpable nodules, and nondiagnostic cytology on previous fine-needle aspiration.∥Perform diagnostic thyroid ultrasound if not previously performed.¶Follicular neoplasm, Hürthle cell neoplasm, suspicious for papillary thyroid cancer.#Insufficient quantity of follicular thyroid cells.
  • Subclinical Thyroid Disease: Clinical Applications

    Abstract Full Text
    free access
    JAMA. 2004; 291(2):239-243. doi: 10.1001/jama.291.2.239
  • Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management

    Abstract Full Text
    free access is expired quiz
    JAMA. 2004; 291(2):228-238. doi: 10.1001/jama.291.2.228
  • Cancer Mortality Following Treatment for Adult Hyperthyroidism

    Abstract Full Text
    free access
    JAMA. 1998; 280(4):347-355. doi: 10.1001/jama.280.4.347
  • Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years?

    Abstract Full Text
    JAMA. 1998; 280(4):375-376. doi: 10.1001/jama.280.4.375
  • JAMA May 26, 2015

    Figure 1: Association Between Subclinical Hyperthyroidism and Fracture Risk

    Hazard ratios (HRs) were adjusted for age and sex. Data marker sizes are proportional to the inverse of the variance of the HRs. Error bars indicate 95% CIs. Not every outcome was available for each study. Calculations of τ2 were used to measure heterogeneity in effect estimates across cohorts, with a prespecified τ2 (≤0.04) indicating low heterogeneity and greater than 0.04 to 0.36 indicating moderate heterogeneity.
  • JAMA May 26, 2015

    Figure 2: Stratified Analyses for the Association Between Subclinical Hyperthyroidism and Fracture Risk

    All hazard ratios (HRs) were age and sex adjusted. Error bars indicate 95% CIs. The multivariable analysis yielded similar results (eTable 3 in Supplement 1).aThe PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) Study was not included because follow-up data were only available for any fracture.bThese HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.cThe HUNT (Nord-Trøndelag Health Study), Cardiovascular Health Study, Sheffield, and OPUS (Osteoporosis and Ultrasound Study) studies were not included because follow-up data for any fracture were not available.dThe HUNT, Cardiovascular Health Study, Leiden 85-Plus, and PROSPER studies were not included because follow-up data for nonspine fractures were not available.eThe HUNT, Cardiovascular Health Study, Leiden 85-Plus, Sheffield, OPUS, and PROSPER studies were not included because follow-up data for spine fractures were not available.
  • JAMA May 26, 2015

    Figure 3: Association Between Subclinical Hyperthyroidism and Fracture Risk Categorized by Thyroid-Stimulating Hormone Level

    All hazard ratios (HRs) were age and sex adjusted. Error bars indicate 95% CIs. The multivariable analysis yielded similar results (eTable 3 in Supplement 1).a The PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) Study was not included because follow-up data were only available for any fracture.b The HUNT (Nord-Trøndelag Health Study), Cardiovascular Health Study, Sheffield, and OPUS (Osteoporosis and Ultrasound Study) studies were not included because follow-up data for any fracture were not available.c The HUNT, Cardiovascular Health Study, Leiden 85-Plus, and PROSPER studies were not included because follow-up data for nonspine fractures were not available.d The HUNT, Cardiovascular Health Study, Leiden 85-Plus, Sheffield, OPUS, and PROSPER studies were not included because follow-up data for spine fractures were not available.
  • JAMA July 20, 2011

    Figure: Hyperthyroidism

  • JAMA July 20, 2011

    Figure: Hyperthyroidism

  • JAMA July 6, 2005

    Figure: Hyperthyroidism

  • Subclinical Thyroid Dysfunction and Fracture Risk: A Meta-analysis

    Abstract Full Text
    free access has multimedia
    JAMA. 2015; 313(20):2055-2065. doi: 10.1001/jama.2015.5161

    The meta-analysis compared levels of subclinical thyroid dysfunction and fracture risk to assess whether treating hyperthyroidism could help prevent fractures.

  • JAMA January 14, 2004

    Figure 2: Suggested Approach to Diagnosis and Management of Subclinical Hyperthyroidism

    TSH indicates thyroid-stimulating hormone; FT4, free T4; FT3, free T3.